COMP <GO>
DFTX vs LLY // FORWARD P/E MULTIPLE
Definium Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: DFTX 2
— LLY 10
▲ FORWARD P/E MULTIPLE LEADER: LLY
LAST: $37.96 (-0.37%) • MKT CAP: $5.10B
forward-pe
33.0x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
forward-pe
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DFTX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DFTX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.20% | 32.36% | -64.56 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.84% | 2.30% | -6.14 | LLY | /fcf-yield <GO> |
| Operating Margin | -11.60% | 40.21% | -51.81 | LLY | /operating-margins <GO> |
| Net Profit Margin | -12.90% | 31.90% | -44.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 5.50% | 45.51% | -40.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | DFTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.4 | 66.6 | -11.20 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.51 | +0.57 | DFTX | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 33.0x | 26.3x | +6.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.10B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DFTX REV | LLY REV | DFTX GROSS % | LLY GROSS % | DFTX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.18B | — | 83.0% | -$131.6M | $16.81B |
| FY 2024 | $0 | $45.04B | — | 81.3% | -$79.1M | $8.82B |
| FY 2023 | $0 | $34.12B | — | 79.3% | -$64.4M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DFTX // BETA 1.08
LLY // BETA 0.51